From ESC: Remote Monitoring for Atrial Fibrillation, Semaglutide and Tirzepatide in Patients With Heart Failure With Preserved Ejection Fraction, RSV Vaccine to Prevent Hospitalizations in Older Adults, and more
- Author
- American Medical Association
- Published
- Mon 01 Sep 2025
- Episode Link
- https://edhub.ama-assn.org/jn-learning/audio-player/10.1001/jama.2025.14786
Special edition of the JAMA Editor's Summary featuring the JAMA Network articles published at the 2025 European Society of Cardiology Congress. Hosted by JAMA Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, with JAMA Executive Editor Gregory Curfman, MD, JAMA Senior Editor Philip Greenland, MD, and JAMA Cardiology Editor Robert O. Bonow, MD, MS. Related Content:
- Remote Screening for Asymptomatic Atrial Fibrillation
- Long-Term Anticoagulation Discontinuation After Catheter Ablation for Atrial Fibrillation
- Systolic Blood Pressure and Microaxial Flow Pump–Associated Survival in Infarct-Related Cardiogenic Shock
- Helicobacter pylori Screening After Acute Myocardial Infarction
- Physiology-Guided Complete Revascularization in Older Patients With Myocardial Infarction
- Fractional Flow Reserve–Guided Complete vs Culprit-Only Revascularization in Non–ST-Elevation Myocardial Infarction and Multivessel Disease
- Transcatheter or Surgical Treatment of Patients With Aortic Stenosis at Low to Intermediate Risk
- Semaglutide and Tirzepatide in Patients With Heart Failure With Preserved Ejection Fraction
- Bivalent RSV Prefusion F Protein–Based Vaccine for Preventing Cardiovascular Hospitalizations in Older Adults
- High-Dose vs Standard-Dose Influenza Vaccine and Cardiovascular Outcomes in Older Adults
- Risk of Myocarditis or Pericarditis With High-Dose vs Standard-Dose Influenza Vaccine
- Clonal Hematopoiesis and Risk of New-Onset Myocarditis and Pericarditis
- Participation of Women in Cardiovascular Trials From 2017 to 2023
- Prevalence, Determinants, and Time Trends of Cardiovascular Health in the WHO African Region
